Tradestie Institutional Equity Comparison Engine · Market Close Apr 06, 2026

HOLX vs CHEK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HOLX Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

HOLX Overall Winner 6-Pillar Tally: HOLX 6 – 0 CHEK Matrix Metrics: HOLX 10 – 0 CHEK

As of Apr 06, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HOLX vs CHEK
HOLX NASDAQ Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$76.01
+0.48% 1D
Market Cap $16.9B
TTM Revenue $4.13B
Forward P/E 20.1x
Beta / 30D Vol 0.08β · 3% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 75.0 Fund 61.0 Flow 54.0 Mom 49.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29
CHEK NASDAQ
Check-Cap Ltd.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$1.61
+1.9% 1D
Market Cap $9.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.94β · 179% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.0 · SMA20: $1.52 · SMA50: $1.80

6-Pillar Scorecard Institutional Category Breakdown (HOLX 6 – 0 CHEK)

Columns: Metric · HOLX · CHEK
1. Valuation Multiples HOLX
Forward P/E 20.1x N/M
Trailing P/E 31.4x N/M
PEG Ratio 1.66x N/M
EV / Revenue 4.1x N/M
2. Growth & Scale HOLX
Revenue Growth (YoY) +2.5% +0.0%
Earnings Growth (YoY) -9.2% +0.0%
TTM Revenue (USD) $4.13B N/A
Market Cap $16.9B $9.2M
3. Profitability & Quality HOLX
Gross Margin 60.4% N/A
Operating Margin 23.0% 0.0%
Net Profit Margin 13.2% 0.0%
Return on Equity (ROE) 10.9% -226.2%
4. Balance Sheet & Cash Flow HOLX
Cash Generation (TTM) $1.35B EBITDA N/A
Cash Flow Margin 32.7% EBITDA Mgn N/A
Net Cash / Leverage $23.51 Book/Sh · 10.9% ROE -226.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HOLX
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 6.3% (3rd %ile) N/A (N/A)
Put/Call OI Skew 6.20x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HOLX
OpEx & R&D Intensity 37.4% of Rev ($1.54B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HOLX (10) vs CHEK (0)
Institutional Metric HOLX CHEK Criterion Row Edge
Market Capitalization
Scale
$16.9B $9.2M Larger Scale HOLX
Trailing P/E Ratio
Valuation
31.4x N/M Lower Multiple HOLX
Forward P/E Ratio
Valuation
20.1x N/M Lower Multiple HOLX
Revenue Growth (YoY)
Growth
+2.5% +0.0% Higher Growth HOLX
Operating Margin (TTM)
Profitability
23.0% 0.0% Higher Margin HOLX
Net Profit Margin
Profitability
13.2% 0.0% Higher Margin HOLX
Return on Equity (ROE)
Capital Efficiency
10.9% -226.2% Higher ROE HOLX
52-Week Range Position
Momentum
100% ($52–$76) 41% ($1–$3) Stronger Trend HOLX
Beta / 30D Volatility
Risk Regime
0.08β · 3% Vol 0.94β · 179% Vol Lower Realized Risk HOLX
Unified Institutional Score
Composite Signal
64.2 / 100 (BUY) 52.1 / 100 (HOLD) Higher Composite HOLX
Trailing 12M Revenue (USD)
Operating Scale
$4.13B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.66x PEG · 4.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE) N/A (-226.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CHEK +6.98 pp
HOLX: +1.07% · CHEK: +8.05%
3M Horizon CHEK +137.72 pp
HOLX: +12.28% · CHEK: +150.0%
6M Horizon CHEK +77.94 pp
HOLX: +18.88% · CHEK: +96.82%
1Y Horizon CHEK +75.26 pp
HOLX: +23.51% · CHEK: +98.77%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs CHEK. Trailing 12-month operating profitability (HOLX 23.0% vs CHEK 0.0%) and valuation multiples (HOLX 20.1x vs CHEK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HOLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.13B
Gross Margin60.4%
Op. Margin23.0%
ROE / Fwd P/E10.9% · 20.1x
CHEK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-226.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HOLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 6.3%
IV Percentile 3rd %ile
Put/Call OI Skew 6.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HOLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CHEK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CHEK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HOLX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($1.54B)
90D Engineering Disclosures 0 Published
CHEK Moat Profile Cyclical / Execution-Driven Positioning
X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator
Competes within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus value chain with $9.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HOLX vs CHEK Key Questions & Quantitative Answers

As of Apr 06, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Check-Cap Ltd. (CHEK) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin). Technically, HOLX sits in a Neutral phase (RSI 69.0, UNCLASSIFIED options structure) and CHEK sits in a Neutral phase (RSI 51.0, UNCLASSIFIED options structure).

HOLX leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with CHEK at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus N/A for CHEK. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CHEK.

HOLX screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas CHEK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus CHEK (-226.2% ROE) capital efficiency.

In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, CHEK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 179% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Apr 06, 2026. For educational research only; not investment advice.